'Out of blue' Lhermitte's sign: Three cases due to low cumulative doses of oxaliplatin

Annals of Oncology

Volumn 19, Issue 12, 2008, Pages 2093-2094

  Jurado, Jose M ^a   Pajares, B ^a   Olmos, D ^a   Sevilla, I ^a   Alba, E ^a  

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; VATALANIB;

ADJUVANT THERAPY; ADULT; CASE REPORT; COLON ADENOCARCINOMA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG INDUCED DISEASE; DRUG RESPONSE; DRUG WITHDRAWAL; DYSESTHESIA; FEMALE; HAND DISEASE; HUMAN; HYPESTHESIA; LETTER; LHERMITTE SIGN; LIMB DYSESTHESIA; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NEUTROPENIA; PARESTHESIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; VISCERAL METASTASIS;

ADENOCARCINOMA; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLONIC NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PARESTHESIA;

EID: 56749175262     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn684     Document Type: Letter

References (7)

1. Dewar J, Lunt H, Abernethy DA et al. Cisplatin neuropathy with Lhermitte's sign. J Neurol Neurosurg Psychiatry 1986; 49: 96-99.
2. Hilkens PH, Verweij J, Vecht CJ et al. Clinical characteristics of severe peripheral neuropathy induced by docetaxel (Taxotere). Ann Oncol 1997; 8: 187-190.
3. Brienza S, Vingoud J, Itzhaki M, Krikorian A. Oxaliplatin: Global safety in 682 patients. Proc Am Soc Clin Oncol 1995; 14: 209 (Abstr 513).
4. Andre T, Bensmaine MA, Louvet C et al. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol 1999; 17: 3560-3568.
5. Taieb S, Trillet-Lenoir V, Rambaud L et al. Lhermitte sign and urinary retention. Atypical presentation of oxaliplatin neurotoxicity in four patients. Cancer 2002; 94: 2434-2440.
6. Ciucci G, De Giorgi U, Leoni M et al. Lhermitte's sign following oxaliplatin-containing chemotherapy in a cisplatin-pretreated ovarian cancer patient. Eur J Neurol 2003; 10: 325-334.
7. Giantonio BJ, Catalano PJ, Meropol NJ et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200. Proc Am Soc Clin Oncol 2005; 23: 2 (Abstr 2).